GIP (glucose-dependent insulinotropic polypeptide): Supports insulin release and may enhance fat metabolism
Because compounded formulations and nonstandard doses aren't FDA-reviewed in the same way as commercial products, medical oversight ensures quality, safety, and proper monitoring
Chiasson, J.L., Acarbose for the prevention of diabetes, hypertension, and cardiovascular disease in subjects with impaired glucose tolerance: the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) Trial
Although weight loss explains part of this effect, studies suggest the relationship between GLP-1 therapy and improved blood pressure control goes deeper
When I started my weight loss journey, I didnt set out and say I wanted to lose a set amount of pounds and weigh a specific weight
You might think that would at least coincide with a superior safety profile, but that same study saw a greater rate of trial discontinuation due to adverse effects in the liraglutide group than in the semaglutide group.7 It also requires daily dosing, which is less convenient than the weekly administration of semaglutide and tirzepatide